Companies:
49,998
Total Market Cap:
142331232390757.59
Global Rank
#18773
Country Rank
#1480
Market Cap
258.41 M
Price
20.33
Change (%)
1.35%
Volume
832,500
Renascience's latest marketcap:
258.41 M
As of 07/28/2025, Renascience's market capitalization has reached $258.41 M. According to our data, Renascience is the 18773th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 258.41 M |
| Revenue (ttm) | 891,470.25 |
| Net Income (ttm) | 763,152.56 |
| Shares Out | 12.71 M |
| EPS (ttm) | 0.06 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/13/2025 |
Market Cap Chart
Data Updated: 07/28/2025
Renascience's yearly market capitalization.
Renascience has seen its market value grow from ¥8.68 B to ¥38.26 B since 2021, representing a total increase of 340.70% and an annual compound growth rate (CAGR) of 51.38%.
| Date | Market Cap(¥) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/28/2025 | ¥38.26 B | $258.41 M | 913.47% | 18773 |
| 12/30/2024 | ¥3.78 B | $24.01 M | -31.57% | 32992 |
| 12/29/2023 | ¥5.52 B | $39.11 M | 18.26% | 29450 |
| 12/30/2022 | ¥4.67 B | $35.55 M | -46.27% | 29194 |
| 12/30/2021 | ¥8.68 B | $75.45 M | 24966 |
Company Profile
About Renascience Inc.
Renascience Inc. is a pharmaceutical and medical device company focused on the development and commercialization of innovative healthcare solutions. Headquartered in Tokyo, Japan, the company was established in 2000.
Key Product Candidates
- RS5614 – A PAI-1 inhibitor currently in Phase 3 clinical trials for chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets.
- RS5441 – A PAI-1 inhibitor in Phase 1 clinical trials for dermatological diseases.
- RS8001 – A water-soluble vitamin in Phase 2 clinical trials for premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder.
Additional Developments
- RS9001 – A disposable ultrafine endoscope under development.
- Artificial intelligence-based medical solutions.
- Diagnostic solutions.
Frequently Asked Questions
-
What is Renascience's (TYO-4889) current market cap?As of 07/28/2025, Renascience (including the parent company, if applicable) has an estimated market capitalization of $258.41 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Renascience (TYO-4889) rank globally by market cap?Renascience global market capitalization ranking is approximately 18773 as of 07/28/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.